SCHEMBL6483228

SCHEMBL6483228

Cc1c(F)cccc1CNc1ccc2[nH]c3ccccc3c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
GAA P10253 3/20 0.51
KMT2A Q03164 4/20 0.46
KDM4E B2RXH2 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.44
MEN1 O00255 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
ATM Q13315 1/20 0.44
PLA2G1B P04054 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
LRRK2 Q5S007 1/20 0.42
LMNA P02545 1/20 0.42
KIF11 P52732 2/20 0.41
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492565 0.84 KMT2A (0.47) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6493014 0.84 KMT2A (0.50) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6492248 0.81 KMT2A (0.47) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6491702 0.81 GAA (0.49) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6496788 0.81 GAA (0.46) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6497640 0.79 KMT2A (0.49) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6483845 0.78 KMT2A (0.50) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6491021 0.78 KIF11 (0.49) MAPTGAAKMT2AKDM4EMTNR1A
SCHEMBL6492990 0.77 RXFP1 (0.44) MAPTGAAKMT2AKDM4EL3MBTL1
SCHEMBL6485068 0.77 MAPT (0.56) MAPTGAAKMT2AKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885GAA 1524/4885KMT2A 412/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885GAA 1297/4885KMT2A 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.